Prostate Specific Antigen Testing Among the Elderly-When To Stop?

Edward M. Schaeffer, H. Ballentine Carter, Anna Kettermann, Stacy Loeb, Luigi Ferrucci, Patricia Landis, Bruce J. Trock, E. Metter

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: Prostate specific antigen testing is common in the elderly despite evidence that older men without aggressive prostate cancer are unlikely to benefit from diagnosis and treatment. We evaluated the relationship between prostate specific antigen and the risk of aggressive prostate cancer developing in men of various ages. Materials and Methods: This longitudinal cohort study consisted of 849 men (122 with and 727 without prostate cancer) with serial prostate specific antigen measurements participating in the Baltimore Longitudinal Study of Aging. The primary outcome measure was the proportion of men by prostate specific antigen and age who died of prostate cancer or in whom aggressive prostate cancer developed (death from prostate cancer, a prostate specific antigen 20 ng/ml or greater, or Gleason score 8 or greater). Results: No participants between 75 and 80 years old with a prostate specific antigen less than 3.0 ng/ml died of prostate cancer. In contrast, men of all ages with a prostate specific antigen of 3.0 ng/ml or greater had a continually increasing probability of death from prostate cancer (Fisher's exact test p <0.001). The time to death or diagnosis of aggressive prostate cancer after age 75 years was not significantly different between the prostate specific antigen categories of 3 to 3.9 and 4 to 9.9 ng/ml (p = 0.634), whereas the time to death or diagnosis of high risk prostate cancer was significantly longer for the prostate specific antigen category of less than 3 vs 3 ng/ml or greater (p = 0.019). Conclusions: Men 75 to 80 years old with a prostate specific antigen less than 3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that prostate specific antigen testing might be safely discontinued for these men.

Original languageEnglish (US)
Pages (from-to)1606-1614
Number of pages9
JournalJournal of Urology
Volume181
Issue number4
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Longitudinal Studies
Baltimore
Neoplasm Grading
Cohort Studies
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Schaeffer, E. M., Carter, H. B., Kettermann, A., Loeb, S., Ferrucci, L., Landis, P., ... Metter, E. (2009). Prostate Specific Antigen Testing Among the Elderly-When To Stop? Journal of Urology, 181(4), 1606-1614. https://doi.org/10.1016/j.juro.2008.11.117

Prostate Specific Antigen Testing Among the Elderly-When To Stop? / Schaeffer, Edward M.; Carter, H. Ballentine; Kettermann, Anna; Loeb, Stacy; Ferrucci, Luigi; Landis, Patricia; Trock, Bruce J.; Metter, E.

In: Journal of Urology, Vol. 181, No. 4, 01.04.2009, p. 1606-1614.

Research output: Contribution to journalArticle

Schaeffer, EM, Carter, HB, Kettermann, A, Loeb, S, Ferrucci, L, Landis, P, Trock, BJ & Metter, E 2009, 'Prostate Specific Antigen Testing Among the Elderly-When To Stop?', Journal of Urology, vol. 181, no. 4, pp. 1606-1614. https://doi.org/10.1016/j.juro.2008.11.117
Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P et al. Prostate Specific Antigen Testing Among the Elderly-When To Stop? Journal of Urology. 2009 Apr 1;181(4):1606-1614. https://doi.org/10.1016/j.juro.2008.11.117
Schaeffer, Edward M. ; Carter, H. Ballentine ; Kettermann, Anna ; Loeb, Stacy ; Ferrucci, Luigi ; Landis, Patricia ; Trock, Bruce J. ; Metter, E. / Prostate Specific Antigen Testing Among the Elderly-When To Stop?. In: Journal of Urology. 2009 ; Vol. 181, No. 4. pp. 1606-1614.
@article{8ef145bd11b848879a541e9f69db87a3,
title = "Prostate Specific Antigen Testing Among the Elderly-When To Stop?",
abstract = "Purpose: Prostate specific antigen testing is common in the elderly despite evidence that older men without aggressive prostate cancer are unlikely to benefit from diagnosis and treatment. We evaluated the relationship between prostate specific antigen and the risk of aggressive prostate cancer developing in men of various ages. Materials and Methods: This longitudinal cohort study consisted of 849 men (122 with and 727 without prostate cancer) with serial prostate specific antigen measurements participating in the Baltimore Longitudinal Study of Aging. The primary outcome measure was the proportion of men by prostate specific antigen and age who died of prostate cancer or in whom aggressive prostate cancer developed (death from prostate cancer, a prostate specific antigen 20 ng/ml or greater, or Gleason score 8 or greater). Results: No participants between 75 and 80 years old with a prostate specific antigen less than 3.0 ng/ml died of prostate cancer. In contrast, men of all ages with a prostate specific antigen of 3.0 ng/ml or greater had a continually increasing probability of death from prostate cancer (Fisher's exact test p <0.001). The time to death or diagnosis of aggressive prostate cancer after age 75 years was not significantly different between the prostate specific antigen categories of 3 to 3.9 and 4 to 9.9 ng/ml (p = 0.634), whereas the time to death or diagnosis of high risk prostate cancer was significantly longer for the prostate specific antigen category of less than 3 vs 3 ng/ml or greater (p = 0.019). Conclusions: Men 75 to 80 years old with a prostate specific antigen less than 3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that prostate specific antigen testing might be safely discontinued for these men.",
author = "Schaeffer, {Edward M.} and Carter, {H. Ballentine} and Anna Kettermann and Stacy Loeb and Luigi Ferrucci and Patricia Landis and Trock, {Bruce J.} and E. Metter",
year = "2009",
month = "4",
day = "1",
doi = "10.1016/j.juro.2008.11.117",
language = "English (US)",
volume = "181",
pages = "1606--1614",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Prostate Specific Antigen Testing Among the Elderly-When To Stop?

AU - Schaeffer, Edward M.

AU - Carter, H. Ballentine

AU - Kettermann, Anna

AU - Loeb, Stacy

AU - Ferrucci, Luigi

AU - Landis, Patricia

AU - Trock, Bruce J.

AU - Metter, E.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Purpose: Prostate specific antigen testing is common in the elderly despite evidence that older men without aggressive prostate cancer are unlikely to benefit from diagnosis and treatment. We evaluated the relationship between prostate specific antigen and the risk of aggressive prostate cancer developing in men of various ages. Materials and Methods: This longitudinal cohort study consisted of 849 men (122 with and 727 without prostate cancer) with serial prostate specific antigen measurements participating in the Baltimore Longitudinal Study of Aging. The primary outcome measure was the proportion of men by prostate specific antigen and age who died of prostate cancer or in whom aggressive prostate cancer developed (death from prostate cancer, a prostate specific antigen 20 ng/ml or greater, or Gleason score 8 or greater). Results: No participants between 75 and 80 years old with a prostate specific antigen less than 3.0 ng/ml died of prostate cancer. In contrast, men of all ages with a prostate specific antigen of 3.0 ng/ml or greater had a continually increasing probability of death from prostate cancer (Fisher's exact test p <0.001). The time to death or diagnosis of aggressive prostate cancer after age 75 years was not significantly different between the prostate specific antigen categories of 3 to 3.9 and 4 to 9.9 ng/ml (p = 0.634), whereas the time to death or diagnosis of high risk prostate cancer was significantly longer for the prostate specific antigen category of less than 3 vs 3 ng/ml or greater (p = 0.019). Conclusions: Men 75 to 80 years old with a prostate specific antigen less than 3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that prostate specific antigen testing might be safely discontinued for these men.

AB - Purpose: Prostate specific antigen testing is common in the elderly despite evidence that older men without aggressive prostate cancer are unlikely to benefit from diagnosis and treatment. We evaluated the relationship between prostate specific antigen and the risk of aggressive prostate cancer developing in men of various ages. Materials and Methods: This longitudinal cohort study consisted of 849 men (122 with and 727 without prostate cancer) with serial prostate specific antigen measurements participating in the Baltimore Longitudinal Study of Aging. The primary outcome measure was the proportion of men by prostate specific antigen and age who died of prostate cancer or in whom aggressive prostate cancer developed (death from prostate cancer, a prostate specific antigen 20 ng/ml or greater, or Gleason score 8 or greater). Results: No participants between 75 and 80 years old with a prostate specific antigen less than 3.0 ng/ml died of prostate cancer. In contrast, men of all ages with a prostate specific antigen of 3.0 ng/ml or greater had a continually increasing probability of death from prostate cancer (Fisher's exact test p <0.001). The time to death or diagnosis of aggressive prostate cancer after age 75 years was not significantly different between the prostate specific antigen categories of 3 to 3.9 and 4 to 9.9 ng/ml (p = 0.634), whereas the time to death or diagnosis of high risk prostate cancer was significantly longer for the prostate specific antigen category of less than 3 vs 3 ng/ml or greater (p = 0.019). Conclusions: Men 75 to 80 years old with a prostate specific antigen less than 3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that prostate specific antigen testing might be safely discontinued for these men.

UR - http://www.scopus.com/inward/record.url?scp=62049083169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62049083169&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.11.117

DO - 10.1016/j.juro.2008.11.117

M3 - Article

VL - 181

SP - 1606

EP - 1614

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -